ANNOUNCEMENTS | 11.20.2026

# Choate Advises Stipple Bio on Strategic Research Collaboration with Eli Lilly

Choate advised long-time IP client Stipple Bio in connection with its multi-target multi-modality strategic research collaboration and license agreement with Eli Lilly and Company, in a transaction valued at up to $5.9 billion dollars upon achievement of research, product development, and commercialization milestones.

Choate's intellectual property team, led by Brian Reese and Melissa Adams, provided intellectual property counsel and deal support to Stipple Bio in connection with the transaction.

Stipple Bio is a precision oncology company developing novel therapies through its proprietary Pointillist Platform, which identifies novel tumor-specific cell surface epitopes to enable the development of precision oncology therapies designed to improve efficacy while reducing on-target, off-tumor toxicity. Stipple is advancing a multi-modality pipeline, including its first-in-class ADC STP-100, while collaborating with Lilly to develop high therapeutic index oncology therapies across multiple modalities. To learn more, please view Stipple Bio's press release.

Choate congratulates the entire Stipple Bio team on this important partnership and looks forward to its continued success in developing life-changing medicines for cancer patients.

**Brian E. Reese, PhD, MBA**
Partner

**Melissa M. Adams, PhD**
Principal

© 2026 Choate, Hall & Stewart LLP | Two International Place, Suite 3000 | Boston, MA 02110 | 617-248-5000